Tag: Envveno Medical
Three-year VenoValve first-in-human trial data published
Envveno Medical has announced that its manuscript titled, "Three-year outcomes of surgical implantation of a novel bioprosthetic valve for the treatment of deep venous...
VenoValve: Analysis finds similar improvement among both primary and thrombotic deep...
A new subanalysis of the SAVVE (Surgical antireflux venous valve endoprosthesis) trial found that there was no difference in the level of improvement in...
One-year SAVVE trial results are ‘most encouraging data ever produced for...
The one-year data from the SAVVE trial represent the “most encouraging clinical data that have ever been produced for a bioprosthetic deep vein valve”...
Positive one-year data for new venous valve portends promising future in...
SAVVE trial principal investigators discuss results showing 98.4% VenoValve device patency, 85% clinically meaningful benefit and an 80% rate of ulcer size reduction at...
One-year data from VenoValve US pivotal trial emerges
Envveno Medical has announced that it will present one-year data on all patients from the VenoValve US pivotal trial today at the VEITHsymposium (19–23 November, New York,...
PMA application submitted for VenoValve device
enVVeno Medical today announced it has submitted an application with the U.S. Food and Drug Administration (FDA) seeking approval to market the VenoValve—a surgical...
First-in-human patients continue to benefit from VenoValve at average of three...
Positive long-term, three-year observational data from a cohort of patients that participated in the previously concluded VenoValve (Envveno Medical) first-in-human clinical trial were recently...